A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Recruiting now · Phase 1
Conditions studied: Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis
In brief
This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases. The primary objectives of this study are: * To evaluate the safety and tolerability of KITE-363 in participants with autoimmune neurologic diseases * To determine the recommended dose for Phase 1b. * To evaluate the preliminary efficacy of KITE-363 in participants with autoimmune neurologic diseases.
Key facts
- Study ID
- NCT07304154
- Run by
- Kite, A Gilead Company
- People needed
- 52
- Starts
- 2026-04-10
- Expected to finish
- 2029-06-01
- Last updated by the study team
- 2026-07-01
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford Neuroscience Health Center — Palo Alto, California, United States (enrolling)
- Columbia University Irving Medical Center — New York, New York, United States (enrolling)
- LDS Hospital - Intermountain Health — Salt Lake City, Utah, United States (enrolling)
- Fred Hutchinson Cancer Center — Seattle, Washington, United States (enrolling)
- Concord Repatriation General Hospital — Sydney, New South Wales, Australia (enrolling)
- Corner Hawkesbury Road and Darcy Road — Westmead, New South Wales, Australia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.